OOIR: Observatory of International Research

Papers

(The H4-Index of World Journal of Gastroenterology is 45. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Difference and clinical value of metabolites in plasma and feces of patients with alcohol-related liver cirrhosis	337
Duodenal-jejunal bypass increases intraduodenal bile acids and upregulates duodenal SIRT1 expression in high-fat diet and streptozotocin-induced diabetic rats	315
Molecular mechanisms implicated in SARS-CoV-2 liver tropism	224
Prognostic performance of an index based on lactic dehydrogenase and transaminases for patients with liver steatosis and COVID-19	209
Advances in paediatric nonalcoholic fatty liver disease: Role of lipidomics	154
GATIS score for predicting the prognosis of rectal neuroendocrine neoplasms: A Chinese multicenter study of 12-year experience	141
Gut microbiome in allogeneic hematopoietic stem cell transplantation and specific changes associated with acute graft vs host disease	126
Mechanism and therapeutic strategy of hepatic TM6SF2-deficient non-alcoholic fatty liver diseases via in vivo and in vitro experiments	119
5-methoxytryptophan induced apoptosis and PI3K/Akt/FoxO3a phosphorylation in colorectal cancer	97
Prostaglandin F_2α synthase promotes oxaliplatin resistance in colorectal cancer through prostaglandin F_2α-dependent and F_2α-independent mechanism	94
SARS-CoV-2 infection in people with pre-existing liver disease: Further research is warranted	92
Urotensin II level is elevated in inflammatory bowel disease patients	90
Targeted metabolomics study of fatty-acid metabolism in lean metabolic-associated fatty liver disease patients	87
What aspects do we overlook in the rehabilitation of patients with inflammatory bowel disease?	87
Expression characteristics of peripheral lymphocyte programmed death 1 and FoxP3⁺ Tregs in gastric cancer during surgery and chemotherapy	84
Increased systemic RNA oxidative damage and diagnostic value of RNA oxidative metabolites during Shigella flexneri-induced intestinal infection	83
Updates in therapeutic drug monitoring in inflammatory bowel disease	83
Current considerations for the management of liver echinococcosis	83
Feasibility of totally laparoscopic gastrectomy without prophylactic drains in gastric cancer patients	80
Schistosomal (bilharzial) polyps: Travel through the colon and beyond	78
Recent advances in the diagnostic evaluation of pancreatic cystic lesions	74
Muscle strength and non-alcoholic fatty liver disease/metabolic-associated fatty liver disease	69
Current and future perspectives on acute-on-chronic liver failure: Challenges of transplantation, machine perfusion, and beyond	68
Similarities, differences, and possible interactions between hepatitis E and hepatitis C viruses: Relevance for research and clinical practice	66
Long-term clinical outcomes of lipiodol marking using standard gastroscopy for image-guided radiotherapy of upper gastrointestinal cancers	65

Divergent trajectories of lean vs obese non-alcoholic steatohepatitis patients from listing to post-transplant: A retrospective cohort study	64
Is there higher percentage of undetected osteopenia and osteoporosis among patients with ulcerative colitis in Saudi Arabia?	63
Systemic treatment for metastatic colorectal cancer	61
Fecal metabolomic profiles: A comparative study of patients with colorectal cancer vs adenomatous polyps	60
Present and future management of viral hepatitis	56
Back to the drawing board: Overview of the next generation of combination therapy for inflammatory bowel disease	55
Regenerating gene 4 promotes chemoresistance of colorectal cancer by affecting lipid droplet synthesis and assembly	54
Safety and effectiveness of vonoprazan-based rescue therapy for Helicobacter pylori infection	54
Preclinical and clinical evidence of the association of colibactin-producing Escherichia coli with anxiety and depression in colon cancer	54
Unresolved conundrum of the role of physical activity in irritable bowel disease: What next?	53
Probiotics: Shaping the gut immunological responses	52
Systemic treatment for unresectable hepatocellular carcinoma	51
Examining dietary interventions in Crohn’s disease	51
Sirtuin 1 in regulating the p53/glutathione peroxidase 4/gasdermin D axis in acute liver failure	50
Updates in diagnosis and management of pancreatic cysts	49
Interaction between inflammatory bowel disease, physical activity, and myokines: Assessment of serum irisin levels	49
Telomerase-related advances in hepatocellular carcinoma: A bibliometric and visual analysis	48
Metabolic dysfunction-associated steatotic liver disease: Navigating terminological evolution, diagnostic frontiers and therapeutic horizon-an editorial exploration	48
Leveraging machine learning for early recurrence prediction in hepatocellular carcinoma: A step towards precision medicine	47
Thymoquinone affects hypoxia-inducible factor-1α expression in pancreatic cancer cells via HSP90 and PI3K/AKT/mTOR pathways	46
Understanding autoimmune pancreatitis: Clinical features, management challenges, and association with malignancies	45
Burden of venous thromboembolism in patients with pancreatic cancer	45
Exosomal microRNAs in hepatocellular carcinoma, rising research filed in hepatocellular carcinoma	45